1
|
Cives M, Hernando J, Lamarca A, Bouvier C, Caplin M, Pavel M. The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients. J Neuroendocrinol 2022; 34:e13196. [PMID: 36072989 PMCID: PMC9786666 DOI: 10.1111/jne.13196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 07/14/2022] [Accepted: 08/17/2022] [Indexed: 12/30/2022]
Abstract
The COVID-19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post-pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID-19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self-injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face-to-face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID-19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation.
Collapse
Affiliation(s)
- Mauro Cives
- Department of Biomedical Sciences and Human OncologyUniversity of Bari “Aldo Moro”BariItaly
| | - Jorge Hernando
- Department of Medical OncologyVall d'Hebron University Hospital, Vall d'Hebron Institute of OncologyBarcelonaSpain
| | - Angela Lamarca
- Department of Medical OncologyThe Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of ManchesterManchesterUK
| | - Catherine Bouvier
- International Neuroendocrine Cancer Alliance (INCA)BostonMassachusettsUSA
| | - Martyn Caplin
- Neuroendocrine Tumor UnitRoyal Free HospitalLondonUK
| | - Marianne Pavel
- Department of Medicine 1, EndocrinologyFriedrich Alexander Universität Erlangen‐NürnbergErlangenGermany
| |
Collapse
|
2
|
The Patient's Point of View: COVID-19 and Neuroendocrine Tumor Disease. Cancers (Basel) 2022; 14:cancers14030613. [PMID: 35158882 PMCID: PMC8833713 DOI: 10.3390/cancers14030613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 01/12/2022] [Accepted: 01/25/2022] [Indexed: 11/17/2022] Open
Abstract
Simple Summary Since neuroendocrine tumor patients require a highly specialized and interdisciplinary infrastructure for diagnostic and therapy, medical care has been very challenging during the COVID-19 pandemic. In cooperation with the patient organization NETZWERK NeT we were able to distribute a comprehensive survey, which has profoundly investigated the healthcare structure and patient-specific concerns during the crisis. In addition to regular medical care, there is a considerable need to measure patient-reported outcomes such as social and emotional distress in a structured way to optimize individual therapy for NET patients. Abstract The assessment of cancer patient care during the COVID-19 pandemic has been mainly reported from a physician’s perspective. Patients with rare tumor entities such as neuroendocrine tumors (NET), which require a complex and specialized care infrastructure, were highly affected by the COVID-19 crisis. Using a structured questionnaire consisting of a general section on the disease and a special COVID-19 section to record medical care, vaccination behavior as well as social and psycho-emotional parameters were collected from NET patients. The survey was distributed via direct medical contact and via the patient organization NETZWERK NeT. A total of 684 patients participated in the survey and 79.2% (n = 542) of the participants answered the questionnaire completely (54 questions). Patient characteristics were comparable to those in large NET registries. The majority of participants were patients with pancreatic and small bowel NET on somatostatin analogue (SSA) therapy. Medical care under COVID-19 was adequate and appointment cancellations and postponements were not common. Nevertheless, the majority of patients were worried about adequate treatment for their tumor disease during the crisis. Most of the participants considered themselves to be at risk of severe COVID-19 infection and were therefore very concerned. This was accompanied by an extremely high vaccination readiness rate of 90%. Increased distress in the social and psycho-emotional domains in the course of the crisis reflected a need for optimization in the medical care of NET patients, although the rate of COVID-19 positive participants was low (3.7%). Therefore, patient-reported measurements are required to identify and address all areas of medical care. Overall, our survey provides an essential contribution to the care of NET patients during the COVID-19 pandemic from the patient’s perspective.
Collapse
|
3
|
Lauricella E, Cives M, Bracigliano A, Clemente O, Felici V, Lippolis R, Amoruso B, Pelle' E, Mandriani B, Esposto C, Forte C, Perri F, Porta C, Tafuto S. The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. J Neuroendocrinol 2021; 33:e13041. [PMID: 34596289 PMCID: PMC8646700 DOI: 10.1111/jne.13041] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 08/06/2021] [Accepted: 09/05/2021] [Indexed: 12/14/2022]
Abstract
The COVID-19 pandemic has added another layer of complexity to the fears of patients with neuroendocrine tumors (NETs). Little is known regarding the psychological impact of the COVID-19 outbreak on patients with gastroenteropancreatic or bronchopulmonary (BP) NETs. We longitudinally surveyed the mental symptoms and concerns of NET patients during the plateau phase of the first (W1) and second epidemic waves (W2) in Italy. Seven specific constructs (depression, anxiety, stress, health-related quality of life, NET-related quality of life, patient-physician relationship, psychological distress) were investigated using validated screening instruments, including DASS-21, EORTC QLQ-C30, EORTC QLQ GI.NET21, PDRQ9 and IES-R. We enrolled 197 patients (98 males) with a median age of 62 years. The majority of the patients had G1/G2 neoplasms. Some 38% of the patients were on active treatment. At W1, the prevalence of depression, anxiety and stress was 32%, 36% and 26% respectively. The frequency of depression and anxiety increased to 38% and 41% at W2, whereas no modifications were recorded in the frequency of stress. Poor educational status was associated with higher levels of anxiety at both W1 (odds ratio [OR] = 1.33 ± 0.22; p = .07) and W2 (OR = 1.45 ± 0.26; p = .03). Notably, post-traumatic stress symptoms were observed in the 58% of the patients, and both single marital status (OR = 0.16, 95% confidence interval [CI] = 0.06-0.48; p = .0009) and low levels of formal education (OR = 0.47, 95% CI = 0.23-0.99; p = .05) predicted their occurrence. No significant deteriorations of health-related quality of life domains were observed from W1 to W2. High patient care satisfaction was documented despite the changes in health systems resource allocation. NET patients have an increased risk of developing post-traumatic stress symptoms as result of the COVID-19 pandemic. Specific screening measures and psychological interventions should be implemented in NET clinics to prevent, recognize and treat mental distress in this vulnerable population.
Collapse
Affiliation(s)
- Eleonora Lauricella
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Mauro Cives
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
- National Cancer Institute, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | | | - Ottavia Clemente
- Istituto Nazionale Tumori, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - Valentina Felici
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Rossella Lippolis
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Brunella Amoruso
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Eleonora Pelle'
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Barbara Mandriani
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Chiara Esposto
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Cira Forte
- Istituto Nazionale Tumori, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - Francesco Perri
- Istituto Nazionale Tumori, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - Camillo Porta
- Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | - Salvatore Tafuto
- Istituto Nazionale Tumori, IRCCS Fondazione "G. Pascale", Naples, Italy
| |
Collapse
|